A detailed history of Dauntless Investment Group, LLC transactions in 89bio, Inc. stock. As of the latest transaction made, Dauntless Investment Group, LLC holds 20,000 shares of ETNB stock, worth $296,800. This represents 0.2% of its overall portfolio holdings.

Number of Shares
20,000
Holding current value
$296,800
% of portfolio
0.2%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$8.02 - $14.96 $160,400 - $299,200
20,000 New
20,000 $293,000

Others Institutions Holding ETNB

About 89bio, Inc.


  • Ticker ETNB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,484,500
  • Market Cap $690M
  • Description
  • 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...
More about ETNB
Track This Portfolio

Track Dauntless Investment Group, LLC Portfolio

Follow Dauntless Investment Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dauntless Investment Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dauntless Investment Group, LLC with notifications on news.